Athersys stem cell therapy could offer new heart attack treatment
Updated 6:31 p.m. While guarding against making too much of a small Phase 1 study, Athersys Inc. (NASDAQ: ATHX) leaders hinted late Wednesday that their adult stem cell therapy MultiStem eventually could change the way people are treated for heart attacks. The Cleveland, Ohio, biopharmaceutical company reported early results from an ongoing Phase 1 trial to determine [...]
[Read the full article here]Related News:
Athersys finishes enrolling heart attack patients for stem cell therapy study
Athersys finishes enrolling heart attack patients for stem cell …
Athersys still looking for funders of stem cell study for stroke patients